First AD

Second AD

Bladder Cancer

Around the Practice

Previously recorded peer-to-peer panel discussions featuring authoritative insights, opinions, and perspectives on case presentations and audience engagement on important issues facing today's cancer care professionals.

2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates

Experts comment on the utility of PARP inhibitors in UC and discuss data presented at ASCO GU 2022. 

ASCO GU 2022 Updates: PARP Inhibitors in First-Line and Subsequent UC Settings

Recent Treatment Advances in Urothelial Cancer

Patient Profile: A 73-Year-Old Woman with Post-Cystectomy mUC

The Role of Biomarkers in Immunotherapy Selection for mUC

JAVELIN Bladder 101: Study Design and Patient Outcomes

Patient-Reported Outcome and Quality of Life Data on Maintenance Therapy

Strategies and Barriers in mUC Maintenance Therapy

Treatment for Cisplatin-Ineligible Patients with High PD-L1 Expression

Maintenance Therapy Duration and Considerations for Treatment Interruption

Treatment Options After Progression on Frontline Maintenance Therapy

Remaining Unmet Needs in Frontline Maintenance Therapy and Ongoing Trials for mUC

ASCO GU 2022 Updates: Trials on Combination Immunotherapy versus Chemotherapy

ASCO GU 2022 Updates: Antibody-Drug Conjugates

Emerging Data and Future Directions in UC

Recap: Treatment Updates in Urothelial Cancer